How Is Aprotinin Stored? Stability, Per the Label and Research

Where Aprotinin Is Handled, and Who Answers Storage Questions

Aprotinin is a prescription medicine administered by specialists in a clinical setting, typically a hospital operating room, an infusion suite or a critical care unit. It is supplied to institutions, stored by hospital pharmacy staff, and drawn up and given by trained clinical personnel. For that reason, storage and stability of aprotinin are institutional pharmacy topics rather than consumer topics, and the authoritative source for any individual product is the approved labeling and carton for that product together with the dispensing pharmacy.

At label level, aprotinin injection has been approved for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in certain patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Availability and the exact wording of the approved indication have varied by country and over time, because marketing of the product was suspended in several regions in 2007 and later reintroduced in some jurisdictions with a restricted indication and added risk minimisation measures. Any use outside an approved indication is investigational. Questions about whether aprotinin is appropriate in a given situation are decided by the prescribing clinician: talk to your prescriber.

Approved Labeling: The Primary Source for Storage Statements

Storage directions for a medicine come from its approved labeling, not from the research literature. Labeling for aprotinin injection has described the product as a sterile, ready to use solution supplied in vials, has specified storage within a controlled temperature range of 2°C to 25°C (36°F to 77°F), and has stated that freezing is to be avoided. Labeling has also described the vials as single use presentations, with any unused solution discarded by the clinical team rather than retained.

Wording differs between manufacturers and between regulatory regions, so statements about light protection, carton storage, shelf life and expiry handling are read from the specific carton and package insert in the hospital pharmacy. The table below separates the source of each type of statement, which is the clearest way to see what is label-derived and what is literature-derived.

Does Aprotinin Need to Be Refrigerated?

The common question of whether aprotinin requires refrigeration is answered by labeling rather than by studies. The labeled range reported for aprotinin injection spans refrigerated and ordinary controlled room temperature conditions, which means the product has not been described as a strictly cold chain item in the way that some biologics are, while still being limited to a defined upper temperature. In practice, hospital pharmacies store the product according to the carton statement for the lot in hand and record storage conditions as part of routine pharmacy quality systems.

Because aprotinin is dispensed only into clinical settings, there is no consumer storage scenario attached to it. Temperature monitoring, excursion handling and quarantine of product that has been exposed to conditions outside the labeled range are managed under institutional policy by pharmacy staff, who also decide when a lot is no longer suitable for use. Those decisions are not made from general reference material.

Freezing, Light and Container Integrity

Labeling for aprotinin injection has described avoidance of freezing, which is consistent with how aqueous protein solutions are generally handled, since freeze and thaw cycles can promote aggregation and particulate formation in protein products. Visual inspection of parenteral solutions for particulate matter and discolouration before use is a standard labeling instruction across injectable products and is carried out by the clinician or pharmacist preparing the dose, not by a patient.

Statements about protection from light vary between aprotinin products and jurisdictions. Where a carton directs retention of the vial in its outer packaging until use, that statement governs. Container integrity matters as well: labeling for injectable solutions routinely addresses intact closures, and hospital pharmacies apply their own receipt inspection procedures. None of these points constitute preparation or administration guidance, which belongs exclusively to the treating specialist team.

In-Use Stability in the Clinical Setting

In-use stability refers to what happens after a vial has been entered or a solution has been transferred into another container. For aprotinin, labeling has framed the vials as single use, which removes the question of storing partially used vials. Where an institution prepares infusions in advance, in-use stability is determined by the approved labeling, by the pharmacy's own validated procedures, and by sterility considerations under national compounding standards, rather than by published pharmacology studies.

This page does not describe preparation, dilution, admixture or administration, and it does not state any dose. Those details sit with the prescribing clinician, the hospital pharmacy and the institutional protocol for the procedure in which aprotinin is used.

Aprotinin Activity and Degradation: What Studies Report

The published literature on aprotinin concerns its biological activity as a broad serine protease inhibitor rather than vial shelf life. That distinction matters when reading stability claims, because a paper that reports preserved inhibitory activity in a culture system is describing an experimental condition, not a storage specification for a medicine.

Inhibition of fibrinolysis in experimental systems

Aprotinin has been widely used in tissue engineering work to slow the breakdown of fibrin based scaffolds, and several studies have characterised how those systems degrade. A 2022 study reported that degradation of gelatin, alginate and fibrin hydrogels was cell type dependent and could be modulated by targeting fibrinolysis (PMID 35935486). A 2018 study described fibrin hydrogels as a xenofree and rapidly degradable support for transplantation of retinal pigment epithelium monolayers (PMID 29233750), and a 2002 report described a fibrin based bioengineered ocular surface carrying human corneal epithelial stem cells (PMID 12072727). A 2018 methods chapter set out three dimensional hydrogel based culture for studying the effects of toxicants on ovarian follicles (PMID 29679322), and a protocol paper described fibrin based endothelial and cardiomyocyte co-culture in a microfluidic device (PMID 42118660). These reports describe laboratory culture conditions and scaffold behaviour; none of them report storage conditions for an approved aprotinin medicine.

Protease inhibitor chemistry and sample handling

Related literature illustrates why protease inhibitors are added when protein containing material is handled. Researchers examined instability of fibroblast growth factor-23 in samples and discussed implications for clinical studies (PMID 21324311), and a separate in vitro study assessed the stability of insulin-like growth factor-I under intestinal conditions (PMID 11782919). The study of insulin microspheres containing a protease inhibitor evaluated those formulations in vitro and in vivo (PMID 21355442). Work on inhibitor chemistry itself has continued as well: researchers purified and characterised tenerplasminin-1, a serine peptidase inhibitor with antiplasmin activity, from coral snake venom (PMID 26419785).

Pathways and models relevant to aprotinin pharmacology

Aprotinin acts on serine proteases including plasmin and plasma kallikrein, and studies of those pathways help explain why its activity is studied at all. One study reported that perfluorohexadecanoic acid increased paracellular permeability in endothelial cells through activation of the plasma kallikrein-kinin system (PMID 28987408). Proteolytic processes in injury have been examined separately, with researchers reporting on the role of myoglobin degradation in nephrotoxicity after rhabdomyolysis (PMID 27329933). In an animal model, a 2000 study reported that aprotinin improved pulmonary function during reperfusion in an isolated lung preparation (PMID 11093508). These are experimental findings in models and do not establish any outcome for an individual patient, and they say nothing about how a vial should be stored.

What the Published Literature Does Not Settle

Readers looking for storage answers should note what the cited literature does not contain. None of the studies above measured potency of a marketed aprotinin product after defined periods at refrigerated or room temperature conditions, after freeze and thaw cycles, or after light exposure. None reported an in-use shelf life for a prepared solution. The literature therefore cannot substitute for the approved labeling, the manufacturer's stability data on file, or the hospital pharmacy's standard operating procedures, all of which are product specific and lot specific.

How Storage Questions Are Framed With the Specialist Team

Because aprotinin is handled only by clinicians and pharmacy staff, storage and stability questions are directed to those professionals. Topics that commonly sit with the treating specialist team and the dispensing pharmacy include:

• The exact storage statement printed on the carton and package insert for the lot in use
• Whether the product in that jurisdiction carries a light protection statement
• Institutional policy on temperature excursions and on quarantine of affected stock
• Whether and for how long a prepared solution may be held before administration
• Current approval status and availability of aprotinin in that country
• Whether aprotinin is appropriate for a specific procedure or patient

For broader background on why temperature, freezing and light are the recurring variables in protein stability discussions, see the general overview of how peptides are stored. That overview covers principles reported across the peptide literature and is not a substitute for the approved labeling of any prescription medicine.

Summary and Disclaimer

Approved labeling for aprotinin injection has described a controlled storage temperature range of 2°C to 25°C, avoidance of freezing, and single use vials, with light and packaging details varying by product and country. Published studies have characterised aprotinin and related protease inhibitors in culture systems and animal models, including reports on fibrin scaffold degradation (PMID 35935486) and on pulmonary function during reperfusion in an isolated lung model (PMID 11093508), but they did not test vial storage conditions. This page is for educational purposes only and is not medical advice; consult a licensed physician or the treating specialist team about any question involving aprotinin.

References

• The degradation of gelatin/alginate/fibrin hydrogels is cell type dependent and can be modulated by targeting fibrinolysis (Frontiers in Bioengineering and Biotechnology, 2022)
• Fibrin hydrogels as a xenofree and rapidly degradable support for transplantation of retinal pigment epithelium monolayers (Acta Biomaterialia, 2018)
• A fibrin-based bioengineered ocular surface with human corneal epithelial stem cells (Cornea, 2002)
• Three-Dimensional Hydrogel-Based Culture to Study the Effects of Toxicants on Ovarian Follicles (Methods in Molecular Biology, 2018)
• Protocol for fibrin-based endothelial-cardiomyocyte co-culture in a microfluidic device (STAR Protocols, 2026)
• Instability of fibroblast growth factor-23 (FGF-23): implications for clinical studies (Clinica Chimica Acta, 2011)
• In vitro assessment of intestinal IGF-I stability (Journal of Pharmaceutical Sciences, 2002)
• In vitro and in vivo evaluation of insulin microspheres containing protease inhibitor (Arzneimittel-Forschung, 2011)
• Purification and characterization of tenerplasminin-1, a serine peptidase inhibitor with antiplasmin activity from the coral snake (Micrurus tener tener) venom (Comparative Biochemistry and Physiology Part C, 2016)
• Perfluorohexadecanoic acid increases paracellular permeability in endothelial cells through the activation of plasma kallikrein-kinin system (Chemosphere, 2018)
• The role of myoglobin degradation in nephrotoxicity after rhabdomyolysis (Chemico-Biological Interactions, 2016)
• Aprotinin improves pulmonary function during reperfusion in an isolated lung model (The Annals of Thoracic Surgery, 2000)